Recent research has unveiled the potential anticancer properties of cannabinoids like THC, CBD, and CBG, sparking optimism for their role in inhibiting tumor growth and improving palliative care. However, despite promising findings, challenges remain in understanding their mechanisms and translating these discoveries into effective clinical applications. The article explores the potential benefits, research gaps, and regulatory hurdles hindering wider adoption of cannabinoids in cancer treatment.